RT Journal Article
SR Electronic
T1 Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: A cross-sectional study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.19.22277546
DO 10.1101/2022.07.19.22277546
A1 Bernal, Jose
A1 Schreiber, Stefanie
A1 Menze, Inga
A1 Ostendorf, Anna
A1 Pfister, Malte
A1 Geisendörfer, Jonas
A1 Nemali, Aditya
A1 Maass, Anne
A1 Yakupov, Renat
A1 Peters, Oliver
A1 Preis, Lukas
A1 Schneider, Luisa
A1 Herrera, Ana Lucia
A1 Priller, Josef
A1 Spruth, Eike Jakob
A1 Altenstein, Slawek
A1 Schneider, Anja
A1 Fliessbach, Klaus
A1 Wiltfang, Jens
A1 Schott, Björn H.
A1 Rostamzadeh, Ayda
A1 Glanz, Wenzel
A1 Buerger, Katharina
A1 Janowitz, Daniel
A1 Ewers, Michael
A1 Perneczky, Robert
A1 Rauchmann, Boris-Stephan
A1 Teipel, Stefan
A1 Kilimann, Ingo
A1 Laske, Christoph
A1 Munk, Matthias H.
A1 Spottke, Annika
A1 Roy, Nina
A1 Dobisch, Laura
A1 Dechent, Peter
A1 Scheffler, Klaus
A1 Hetzer, Stefan
A1 Wolfsgruber, Steffen
A1 Kleineidam, Luca
A1 Schmid, Matthias
A1 Berger, Moritz
A1 Jessen, Frank
A1 Wirth, Miranka
A1 Düzel, Emrah
A1 Ziegler, Gabriel
YR 2023
UL http://medrxiv.org/content/early/2023/01/17/2022.07.19.22277546.abstract
AB Background Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer’s disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just arterial hypertension—impacts WMH, adversely influencing cognition. Here we seek to determine the effect of both hypertension and Aβ positivity on WMH, and their impact on cognition.Methods We analysed data from subjects with a low vascular profile and normal cognition (NC), subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study (n=375, median age 70.2 [IQR 66.0-74.4] years; 176 female; NC/SCD/MCI 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on baseline memory and executive function—derived from multiple neuropsychological tests using confirmatory factor analysis—, baseline preclinical Alzheimer’s cognitive composite 5 (PACC5) scores, and changes in PACC5 scores over course of three years (ΔPACC5).Results Subjects with hypertension or Aβ positivity presented the largest WMH volumes (pFDR<0.05), with spatial overlap in the frontal (hypertension: 0.42±0.17; Aβ: 0.46±0.18), occipital (hypertension: 0.50±0.16; Aβ: 0.50±0.16), parietal lobes (hypertension: 0.57±0.18; Aβ: 0.56±0.20), corona radiata (hypertension: 0.45±0.17; Aβ: 0.40±0.13), optic radiation (hypertension: 0.39±0.18; Aβ: 0.74±0.19), and splenium of the corpus callosum (hypertension: 0.36±0.12; Aβ: 0.28±0.12). Hypertension, Aβ positivity, and WMH were connected to cognition. First, WMH coincided with worse cognitive performance and outcomes (pFDR<0.05), regardless of Aβ and hypertension. Accelerated cognitive decline was associated with WMH in the genu of the corpus callosum and segments of the forceps major and inferior fronto-occipital longitudinal fasciculus (pFDR<0.05). Second, hypertension was indirectly linked to cognitive performance at baseline and over time via splenial WMH (indirect-only effect; memory: −0.05±0.02, pFDR=0.029; executive: −0.04±0.02, pFDR=0.067; PACC5: −0.05±0.02, pFDR=0.030; ΔPACC5: −0.09±0.03, pFDR=0.043). Third, the relationship between Aβ positivity and baseline and longitudinal cognitive performance was independent of WMH burden.Conclusions Posterior white matter is susceptible to hypertension and Aβ accumulation and it mediates the association between hypertension and cognitive dysfunction. Posterior WMH could be a promising target to tackle the downstream damage related to the potentially interacting and potentiating effects of the two pathologies.Trial Registration German Clinical Trials Register (DRKS00007966, 04/05/2015)Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the German Center for Neurodegenerative Diseases (DZNE; reference number BN012) and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Project IDs 425899996 and 362321501/RTG 2413 SynAGE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethical committees of the medical faculties of all participating sites: the ethical committees of Berlin (Charite, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn. All commitees gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript Aββ-amyloidADAlzheimer’s diseaseATNAmyloid/Tau/NeurodegenerationBregression coefficientCAACerebral amyloid angiopathyCERADConsortium to Establish a Registry for Alzheimer’s DiseaseCNNon-complaining healthy controlsCSFCerebrospinal fluidCSVDCerebral small vessel diseaseFDRFalse discovery rateFLAIRFluid Attenuated Inversion RecoveryGMGrey matterIQRInterquartile rangeMCIMild cognitive impairmentMRIMagnetic resonance imagingNCNormal cognitionPACC5Preclinical Alzheimer’s Cognitive Composite 5ROIRegion of interestSCDSubjective cognitive declineSDStandard deviationSEStandard errorSPMStatistical parametric mappingTICVTotal intracranial volumeWMWhite matterWMHWhite matter hyperintensities